SBIR/STTR Research Award
TAS::75 0893::TAS RAPID LARGE SCALE PRODUCTION OF PROTEIN THERAPEUTICS
Award amount
$150,000Program and phase
SBIR · Phase IAward year
2011Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- ANTAGEN BIOSCIENCES INC
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- HXD6EFH2ND57
- Solicitation number
- Not reported
- Topic code
- NIDA
Research abstract
AWith a long-term objective to efficiently manufacture protein therapeutics, the Contractor developed a mammalian expression vector pATG that incorporates human DNA regulatory elements to render long-term cell line stability, ensures the most stringent selection of high producers, and uses the strongest signal sequence for high level secretory expression without gene amplification. This system shortens mamallina cell line development from 1 year to 4-5 weeks. To make this system user-friendly, in this Phase I study, the Contractor will devise novel ways to further reduce cell line development time to 2 weeks; and demonstrate the robustness of its new system by comparing with commercially available vectors in manufacturing model proteins. The Contractor will provide contract CMO services for generating stable, high-producing CHO cells lines for large-scale production of recombinant antibodies and vaccines.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- FcRider-based Expression and Delivery of Stable Env Immunogens for HIV Vaccines
- Development of afucosylated monoclonal antibodies with enhanced effector functions to combat malaria
- SBIR TOPIC 081: ADJUVANT DEVELOPMENT FOR VACCINES AGAINST INFECTIOUS OR IMMUNE-MEDIATED DISEASES
- Nanoparticle Delivery of HIV Env Trimer for Inducing Somatic Hypermutation and bNAb
- The purpose of this contract is to evaluate and modulate the molecular pathways involved in regulating and enhancing HIV envelope/antigen expression in mammalian cell lines and to accelerate development of purification platforms in a cGMP manufacturing se
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Wearable Wireless Respiratory Monitoring System that Detects and Predicts Opioid Induced Respiratory Depression
- Building and testing the Life Enhancement and Advocacy Programming digital training tool (LEAPLink) to better serve people with lived experience of homelessness and substance use disorder
- A digital intervention to decrease self-stigma among pregnant and postpartum women with opioid use disorder
- Development of medication for the treatment of respiratory depression due to opioid (prescribed or illicit) overdose/multidrug (polysubstance) overdose in a hospital or community setting.
- Creation and Validation of the Dose-Opioid-Source Evaluation tool (DOSE) - a Robust Opioid Use Clinical Outcome Assessment for Qualification as an FDA Medical Device Development Tool (MDDT)
Research funding history
8 SBIR/STTR records share this UEI (2011–2022). Reported award amounts total $3,699,909. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services